Modeling and optimization of nanoemulsion containing Sorafenib for cancer treatment by response surface methodology

The aim of this study is the development of nanoemulsions for intravenous administration of Sorafenib, which is a poorly soluble drug with no parenteral treatment. The formulation was prepared by a high energy emulsification method and optimized by response surface methodology. The effects of overhe...

Full description

Bibliographic Details
Main Authors: Izadiyan, Z. (Author), Basri, M. (Author), Fard Masoumi, H. R. (Author), Abedi Karjiban, R. (Author), Salim, N. (Author), Shameli, K. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd., 2017.
Subjects:
Online Access:Get fulltext
LEADER 01785 am a22001933u 4500
001 75905
042 |a dc 
100 1 0 |a Izadiyan, Z.  |e author 
700 1 0 |a Basri, M.  |e author 
700 1 0 |a Fard Masoumi, H. R.  |e author 
700 1 0 |a Abedi Karjiban, R.  |e author 
700 1 0 |a Salim, N.  |e author 
700 1 0 |a Shameli, K.  |e author 
245 0 0 |a Modeling and optimization of nanoemulsion containing Sorafenib for cancer treatment by response surface methodology 
260 |b BioMed Central Ltd.,   |c 2017. 
856 |z Get fulltext  |u http://eprints.utm.my/id/eprint/75905/1/KamyarShameli_ModelingandOptimizationofNanoemulsion.pdf 
520 |a The aim of this study is the development of nanoemulsions for intravenous administration of Sorafenib, which is a poorly soluble drug with no parenteral treatment. The formulation was prepared by a high energy emulsification method and optimized by response surface methodology. The effects of overhead stirring time, high shear rate, high shear time, and cycles of high-pressure homogenizer were studied in the preparation of nanoemulsion loaded with Sorafenib. Most of the particles in nanoemulsion are spherical in shape, the smallest particle size being 82.14nm. The results of the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole reveal that the optimum formulation does not affect normal cells significantly in low drug concentrations but could remove the cancer cells. Finally, a formulation containing Sorafenib retained its properties over a period of 90days. With characterization, the study of the formulated nanoemulsion has the potential to be used as a parenteral nanoemulsion in the treatment of cancer. Graphical abstract Schematic figure of high pressure homogenizer device. 
546 |a en 
650 0 4 |a T Technology (General)